Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration Beyond One Year of Treatment: AZURE, a Randomized Trial of Treat-and-Extend vs. Fixed Dosing-Reference-Cited by-同舟云学术

Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration Beyond One Year of Treatment: AZURE, a Randomized Trial of Treat-and-Extend vs. Fixed Dosing

Published:2024-01-06 Issue:3 Volume:41 Page:1010-1024
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

Kodjikian Laurent^ORCID,Arias Barquet Lluís,Papp András,Kertes Peter J.^ORCID,Midena Edoardo,Ernest Jan,Silva Rufino^ORCID,Schmelter Thomas^ORCID,Niesen Tobias,Leal Sergio

Funder

Bayer

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s12325-023-02719-3.pdf

Reference12 articles.

1. Gale RP, Mahmood S, Devonport H, Patel PJ, Ross AH, Walters G, et al. Action on neovascular age-related macular degeneration (nAMD): recommendations for management and service provision in the UK hospital eye service. Eye (Lond). 2019;33(Suppl 1):1–21.

2. Lanzetta P, Loewenstein A, Vision ASC. Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases. Graefes Arch Clin Exp Ophthalmol. 2017;255(7):1259–73.

3. Patel PJ, Devonport H, Sivaprasad S, Ross AH, Walters G, Gale RP, et al. Aflibercept treatment for neovascular AMD beyond the first year: consensus recommendations by a UK expert roundtable panel, 2017 update. Clin Ophthalmol. 2017;11:1957–66.

4. Khurana RN, Rahimy E, Joseph WA, Saroj N, Gibson A, Vitti R, et al. Extended (every 12 weeks or longer) dosing interval with intravitreal aflibercept and ranibizumab in neovascular age-related macular degeneration: post hoc analysis of VIEW trials. Am J Ophthalmol. 2019;200:161–8.

5. Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, Brown DM, Chong V, Nguyen QD, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology. 2014;121(1):193–201.